Results: IRADIMED CORPORATION Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St.11-03

IRADIMED CORPORATION (NASDAQ:IRMD) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480136616?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","is_english":true,"pubTime":"2024-11-03 21:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480136616","market":"us","top_or_hot":-1,"title":"Results: IRADIMED CORPORATION Exceeded Expectations And The Consensus Has Updated Its Estimates","media":"Simply Wall St.","content":"<div>\n<p>IRADIMED CORPORATION (NASDAQ:IRMD) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/results-iradimed-corporation-exceeded-expectations-130103460.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Results: IRADIMED CORPORATION Exceeded Expectations And The Consensus Has Updated Its Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResults: IRADIMED CORPORATION Exceeded Expectations And The Consensus Has Updated Its Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-03 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/results-iradimed-corporation-exceeded-expectations-130103460.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IRADIMED CORPORATION (NASDAQ:IRMD) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/results-iradimed-corporation-exceeded-expectations-130103460.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://finance.yahoo.com/news/results-iradimed-corporation-exceeded-expectations-130103460.html","article_id":"2480136616","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480136616","pubTimestamp":1730638863,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"IRADIMED CORPORATION  shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a credible result overall - although revenues of US$18m were in line with what the analysts predicted, IRADIMED surprised by delivering a statutory profit of US$0.40 per share, a notable 14% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's t","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IRMD":"iRadimed Corporation"},"translate_title":"结果：IRADIMED CORPORATION超出预期，共识更新了其估计","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1},"content_text":"IRADIMED CORPORATION (NASDAQ:IRMD) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to US$48.30 in the week after its latest third-quarter results. It looks like a credible result overall - although revenues of US$18m were in line with what the analysts predicted, IRADIMED surprised by delivering a statutory profit of US$0.40 per share, a notable 14% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. \n Check out our latest analysis for IRADIMED \n\n\n\n  NasdaqGM:IRMD Earnings and Revenue Growth November 3rd 2024\n \n\n Following the latest results, IRADIMED's twin analysts are now forecasting revenues of US$80.7m in 2025. This would be a meaningful 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 9.2% to US$1.61. In the lead-up to this report, the analysts had been modelling revenues of US$80.4m and earnings per share (EPS) of US$1.62 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. \n With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 14% to US$60.00. It looks as though they previously had some doubts over whether the business would live up to their expectations. \n One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that IRADIMED's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 10% growth on an annualised basis. This is compared to a historical growth rate of 17% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.2% per year. So it's pretty clear that, while IRADIMED's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. \nThe Bottom Line \n The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. \n Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for IRADIMED going out as far as 2026, and you can see them free on our platform here. \n However, before you get too enthused, we've discovered 1 warning sign for IRADIMED that you should be aware of. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480136616"}